PBH - Prestige Consumer Healthcare Inc.
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
While 63% say women are more comfortable discussing intimate wellness than five years ago, new research reveals a gap between cultural progress and personal comfort TARRYTOWN, N.Y., Sept. 30, 2026 /PRNewswire/ -- Women may be talking more openly about intimate health and wellness, but that does not necessarily mean the discomfort has disappeared.
Premium Brands Holdings Co. (TSE: PBH - Get Free Report) hit a new 52-week low during trading on Wednesday. The company traded as low as C$75.25 and last traded at C$75.55, with a volume of 13629 shares changing hands. The stock had previously closed at C$75.79. Analysts Set New Price Targets PBH has been the subject
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026 at 12:45 p.m.
National survey commissioned by DenTek, the #1 OTC dental guard brand for nighttime teeth grinding, finds nearly 8 in 10 football fans keep thinking about the game after it ends, with many reporting stress-related behaviors that extend into bedtime. NFL legends Ronde & Tiki Barber join DenTek to encourage fans to recognize when football stress may be affecting more than just game day.
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Prestige Brand Holdings is recalling 39,060 bottles of certain Clear Eyes drops over sterility concerns, according to a Food and Drug Administration report.
Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway.
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Premium Brands TSE: PBH said its revised 2026 outlook reflects timing shifts in U.S. customer programs and the exit of a low-margin Ontario facility, rather than a deterioration in the company's underlying operating assumptions.
California State Teachers Retirement System boosted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 21.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,310 shares of the company's stock after acquiring an additional 10,117 shares during
Prestige Consumer Healthcare NYSE: PBH reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breathe Right and LaCorium Health while maintaining its prior outlook for organic revenue growth.
Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.95 per share a year ago.
TARRYTOWN, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2027 ended June 30, 2026.
Bank of New York Mellon Corp cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 4.2% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 311,341 shares of the company's stock after selling 13,557 shares during the quarter. Bank